Foxo4-DRI vs HLDF-6

D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated senescent secretory phenotype (SASP) while sparing non-senescent cells in which this interaction is not tonically antiapoptotic. In senescent cells, overexpressed FOXO4 sequesters p53 in the nucleus and prevents it from initiating apoptosis, enabling the persistence of metabolically active senescent cells that secrete pro-inflammatory SASP cytokines; FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, freeing p53 to activate its apoptotic transcriptional program specifically in cells where the FOXO4 sequestration is functionally relevant. The foundational study published in Cell demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells in vivo in mice, restoring tissue homeostasis in both chemotherapy-induced and naturally aged animals; subsequent molecular modeling work has characterized the FOXO4-TP53 interaction interface to guide further senolytic peptide design, though published evidence in humans is absent and the preclinical literature remains limited. FOXO4-DRI is a research compound with no regulatory approval in any jurisdiction; it has been studied only in preclinical animal models, and no human pharmacokinetic, safety, or clinical efficacy data has been established.

Modulates cholinergic neurotransmission. Reduces amyloid-β toxicity and protects against oxidative stress-induced neuronal damage. May enhance memory consolidation via acetylcholine pathway upregulation.

HLDF-6 (human leukemia differentiation factor hexapeptide; TGENHR) is a synthetic hexapeptide derived from a sequence of the HLDF protein, investigated in preclinical models for neuroprotective properties in conditions including Alzheimer's disease and Parkinson's disease, where it is proposed to reduce neuroinflammation, protect against beta-amyloid toxicity, and attenuate dopaminergic neuron loss. HLDF-6 is proposed to modulate inflammatory cytokines and oxidative stress pathways, with potential effects on acetylcholinesterase activity; preclinical animal studies in transgenic Alzheimer's models and MPTP-induced Parkinson's models suggest cognitive-protective properties at the cellular and behavioral level. No published human clinical trials, pharmacokinetic studies, or safety evaluations of HLDF-6 administration have been indexed in PubMed; the entirety of its evidence base consists of rodent and cell-based studies, and no regulatory authority has evaluated or approved HLDF-6 for any human indication. HLDF-6 has no FDA approval or regulatory approval in any jurisdiction; it is a neuroprotective research compound with a defined mechanistic hypothesis and an exclusively preclinical evidence base, and the translation of its animal model findings to human therapeutic outcomes has not been investigated.